1. Home
  2. CULP vs ICCM Comparison

CULP vs ICCM Comparison

Compare CULP & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Culp Inc.

CULP

Culp Inc.

N/A

Current Price

$3.52

Market Cap

52.7M

ML Signal

N/A

Logo IceCure Medical Ltd.

ICCM

IceCure Medical Ltd.

HOLD

Current Price

$0.59

Market Cap

43.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CULP
ICCM
Founded
1972
2006
Country
United States
Israel
Employees
N/A
N/A
Industry
Textiles
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
52.7M
43.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CULP
ICCM
Price
$3.52
$0.59
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$2.50
AVG Volume (30 Days)
20.7K
214.8K
Earning Date
03-04-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$204,919,000.00
$2,975,000.00
Revenue This Year
N/A
$19.87
Revenue Next Year
$6.83
$31.38
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.33
$0.54
52 Week High
$5.64
$1.66

Technical Indicators

Market Signals
Indicator
CULP
ICCM
Relative Strength Index (RSI) 44.38 41.95
Support Level $3.42 $0.59
Resistance Level $3.69 $0.63
Average True Range (ATR) 0.13 0.03
MACD -0.01 -0.00
Stochastic Oscillator 18.51 40.74

Price Performance

Historical Comparison
CULP
ICCM

About CULP Culp Inc.

Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.

About ICCM IceCure Medical Ltd.

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

Share on Social Networks: